These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25636420)

  • 1. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.
    Chapiro J; Duran R; Lin M; Schernthaner R; Lesage D; Wang Z; Savic LJ; Geschwind JF
    Eur Radiol; 2015 Jul; 25(7):1993-2003. PubMed ID: 25636420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival.
    Chapiro J; Duran R; Lin M; Mungo B; Schlachter T; Schernthaner R; Gorodetski B; Wang Z; Geschwind JF
    Eur J Radiol; 2015 Mar; 84(3):424-430. PubMed ID: 25542065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
    Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
    Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
    Sahu S; Schernthaner R; Ardon R; Chapiro J; Zhao Y; Sohn JH; Fleckenstein F; Lin M; Geschwind JF; Duran R
    Radiology; 2017 Jun; 283(3):883-894. PubMed ID: 27831830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival.
    Fleckenstein FN; Schernthaner RE; Duran R; Sohn JH; Sahu S; Zhao Y; Hamm B; Gebauer B; Lin M; Geschwind JF; Chapiro J
    Eur Radiol; 2016 Sep; 26(9):3243-52. PubMed ID: 26762942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
    Doemel LA; Chapiro J; Laage Gaupp F; Savic LJ; Kucukkaya AS; Petukhova A; Tefera J; Zeevi T; Lin M; Schlachter T; Jaffe A; Strazzabosco M; Patel T; Stein SM
    Eur Radiol; 2021 May; 31(5):2737-2746. PubMed ID: 33123796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
    Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J
    Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative volumetric functional MR imaging: an imaging biomarker of early treatment response in hypo-vascular liver metastasis patients after yttrium-90 transarterial radioembolization.
    Zhu X; Sobhani F; Xu C; Pan L; Ghasebeh MA; Kamel IR
    Abdom Radiol (NY); 2016 Aug; 41(8):1495-504. PubMed ID: 26960726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
    Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
    Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment.
    Assouline J; Cannella R; Porrello G; de Mestier L; Dioguardi Burgio M; Raynaud L; Hentic O; Cros J; Tselikas L; Ruszniewski P; Vullierme MP; Vilgrain V; Duran R; Ronot M
    Radiol Imaging Cancer; 2023 Jan; 5(1):e220051. PubMed ID: 36607243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy.
    Ghani MA; Fereydooni A; Chen E; Letzen B; Laage-Gaupp F; Nezami N; Deng Y; Gan G; Thakur V; Lin M; Papademetris X; Schernthaner RE; Huber S; Chapiro J; Hong K; Georgiades C
    Eur Radiol; 2021 Dec; 31(12):8858-8867. PubMed ID: 34061209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
    Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
    Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
    Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
    Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.
    Fleckenstein FN; Schernthaner RE; Duran R; Sohn JH; Sahu S; Marshall K; Lin M; Gebauer B; Chapiro J; Salem R; Geschwind JF
    Transl Oncol; 2016 Oct; 9(5):377-383. PubMed ID: 27641641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
    Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy.
    Akinwande O; Philips P; Scoggins CR; Kelly L; Tatum C; Hahl M; McMasters KM; Martin RC
    J Surg Oncol; 2016 Mar; 113(4):443-8. PubMed ID: 27060707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.